Question-and-Answer Session
Operator
(Operator Instructions). We will take our first question from Edward Tenthoff with Piper Jaffray.
Edward Tenthoff - Piper Jaffray
Hi Marsha. Congratulations on a very nice quarter.
Deborah Dunsire
Thanks.
Marsha Fanucci
Thank you.
Edward Tenthoff - Piper Jaffray
Looking into the U.S. market sales strength, how much of that can you attribute to the co-promotion efforts by J&J and the approval with DOXIL. Can you give us a little bit more color on where that strength came from?
Kyle Kuvalanka
Ted, we are going to have Christophe answer that question.
Edward Tenthoff - Piper Jaffray
Thanks.
Christophe Bianchi
Thank you for the question. We indeed have had a very strong quarter driven by the strength of VELCADE, our enhanced sales and marketing initiative and the co-promotion with OBI. So, if you could to look at this as a whole, we are working with a great brand, we've have got an enhanced sales and marketing initiative that put together a Millennium OBI co-promotion.
So, this is what has led to our dynamic sales growth and we expect this momentum to continue. It is difficult to determine the exact impact of any one of those component. Again we remain very pleased with the OBI co-promotion. So, that's all I can tell you at this stage of the game. We cannot release these out the respective role each of those components.
Edward Tenthoff - Piper Jaffray
Excellent, thank you very much.
Operator
And we will take our next question from Chris Raymond with Robert W. Baird & Company.
Chris Raymond - Robert W. Baird & Company
Hi, thanks. Just a couple of questions on VELCADE. Is there any dynamic to inventory that happens this quarter that you can talk about?
Kyle Kuvalanka
Chris, Christophe is going to take that question.
Christophe Bianchi
As I said in my comments, the inventory remained at the low end of our desired range of 1 to 2 weeks this quarter. So, the inventory was effectively stable and it doesn't change in the third quarter of this year versus the second quarter of this year.
Chris Raymond - Robert W. Baird & Company
So, just to be clear. The number was not helped along by any inventory build.
Christophe Bianchi
No.
Deborah Dunsire
No.
Chris Raymond - Robert W. Baird & Company
Okay, good. Just wanted to clarify it. Secondly, can you maybe talk knowing it's a off-label area, you don't promote front-line multiple myeloma? But, where do you think VELCADE share at this point is, a sort of shaking out in that setting?
- To read the full transcript on Seeking Alpha, click here »
